 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | zenuzolac (VGX-1027) / GeneOne
Trial completion date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Aug 27, 2024
P2, N=132, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Trial completion date: Dec 2023 --> Dec 2024
- | zenuzolac (VGX-1027) / GeneOne
Trial completion date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Sep 13, 2023
P2, N=132, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Jun 2023 --> Dec 2023
- | zenuzolac (VGX-1027) / GeneOne
Trial completion date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - May 26, 2023
P2, N=132, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Trial completion date: Jun 2023 --> Dec 2023 Trial completion date: Mar 2023 --> Jun 2023
- | zenuzolac (VGX-1027) / GeneOne
Trial completion date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Jan 11, 2023
P2, N=132, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Trial completion date: Mar 2023 --> Jun 2023 Trial completion date: Oct 2022 --> Mar 2023
- || zenuzolac (VGX-1027) / GeneOne
Enrollment closed: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Jun 27, 2022
P2, N=132, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Trial completion date: Oct 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- || zenuzolac (VGX-1027) / GeneOne
Trial completion date, Trial primary completion date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Jun 2, 2021
P2, N=132, Recruiting, Sponsor: GeneOne Life Science, Inc.
Recruiting --> Active, not recruiting Trial completion date: Nov 2021 --> Sep 2022 | Trial primary completion date: Oct 2021 --> May 2022
- | VGX-1027 / GeneOne
Journal, IO biomarker: Free light chains injure proximal tubule cells through STAT1-HMGB1-TLR axis. (Pubmed Central) - May 22, 2021
Countering TLR2, TLR4, and TLR6 through GIT-27 or specific TLR siRNAs reduced downstream cytokine responses...PTCs exposed to FLCs released HMGB1, which induced TLRs 2, 4, 6 expression and downstream inflammation. Blocking FLCs' endocytosis, Stat1 knock-down, HMGB1 inhibition, and TLR knock-down each rescued PTCs from FLC-induced injury.
- | VGX-1027 / GeneOne
Preclinical, Journal: Interleukin-1 beta induces autophagy of mouse preimplantation embryos and improves blastocyst quality. (Pubmed Central) - May 11, 2021
Effects of IL-1β on the development of embryo reduced in 20 ng/mL IL-1β supplemented group when 5 mM 3-methyladenine (3-MA) was also added, which used to inhibit autophagy activation in endogenous PtdIns3Ks signal pathway. Our current results show that exogenous IL-1β can effectively induce autophagy in mouse embryos at stages of 2 to 8 cell and blastocyst, that also help to improve the quality of blastocyst.
- ||| zenuzolac (VGX-1027) / GeneOne
Enrollment open: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Apr 8, 2021
P2, N=132, Recruiting, Sponsor: GeneOne Life Science, Inc.
Our current results show that exogenous IL-1β can effectively induce autophagy in mouse embryos at stages of 2 to 8 cell and blastocyst, that also help to improve the quality of blastocyst. Not yet recruiting --> Recruiting
- || zenuzolac (VGX-1027) / GeneOne
Trial initiation date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Feb 3, 2021
P2, N=132, Not yet recruiting, Sponsor: GeneOne Life Science, Inc.
Not yet recruiting --> Recruiting Initiation date: Nov 2020 --> Feb 2021
- |||| zenuzolac (VGX-1027) / GeneOne
New P2 trial: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Oct 18, 2020
P2, N=132, Not yet recruiting, Sponsor: GeneOne Life Science, Inc.
- | Tecfidera (dimethyl fumarate) / Biogen
Journal: Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury. (Pubmed Central) - Jan 24, 2020
GIT-27NO is a NO-derivative of the toll-like receptor 4 antagonist VGX-1027 that has been shown to possess both antineoplastic and immunomodulatory properties in vitro and in vivo...These effects were almost similar to that of the positive control drug dimethyl fumarate. These data suggest that the beneficial effect of GIT-27NO in the hepatic IRI can be secondary to anti-oxidative effects and hepatocyte necrosis reduction probably mediated by NO release.
- | VGX-1027 / GeneOne
Journal: The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4 T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T Itpr3/J mice. (Pubmed Central) - Nov 27, 2019
Moreover, this agent was also found to significantly decrease IL-1β, IL-6, TNF-α, IFN-γ, COX-2, and NOS2 levels and increase IL-10 expression at the protein and mRNA level in brain tissues. Based on results using BTBR mice, our data provide the first evidence that VGX-1027 could potentially be used for the amelioration of autism-like symptoms.